Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Their results showed that GLP-1, a peptide that semaglutide mimics, significantly increased the activity of these cells.

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Semaglutide belongs to a class of medications called glucagon-like peptide-1 receptor agonists, or GLP-1s. These prescription drugs mimic the GLP-1 hormone, which is made naturally in the gut.

Semaglutide is a widely prescribed antidiabetic medicine that acts as a glucagon-like peptide 1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes and obesity. A 2024 study by ...